Functionally enhanced engineered immune cells and their preparation and application
By expressing IL-7 and TGFβRII dominant inhibitory mutants and regulating IL-7 and TGFβ signaling pathways, the problem of insufficient survival and killing ability of CAR-T cells in the tumor microenvironment is solved, and more efficient immune cell therapy is achieved.
Patent Information
- Application Number
- CN202310329934.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-03-30
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2043-03-30
AI Technical Summary
The existing CAR-T cell therapies have problems such as low proliferation ability, short survival period, and large toxic and side effects, making it difficult to effectively survive and effectively kill tumor cells in the tumor immune microenvironment.
By expressing exogenous IL-7 protein and TGFβRII dominantly inhibiting mutants or shRNA targeting endogenous TGFβRII transcripts, regulating IL-7 and TGFβ signaling pathways, improving the proliferation ability of immune cells and resistance to the tumor microenvironment.
It significantly improves the proliferation ability of immune cells, prolongs survival time, reduces toxic side effects, and enhances the killing effect on tumor cells.
Smart Images

Figure BDA0004154617230000243 
Figure BDA0004154617230000244 
Figure BDA0004154617230000246
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of tumor immunity and cell therapy, and specifically relates to function-enhanced engineered immune cells and their preparation and application. Background Art
[0002] T cells are an important type of lymphocyte involved in cellular immunity. With the help of antigen-presenting cells, they can specifically recognize and kill tumor cells. However, tumor cells can also hinder the specific recognition of T cells by reducing or losing antigen epitopes, building an immunosuppressive microenvironment, and evolving tumors of different heterogeneity (i.e., differences in genotype and phenotype between the same malignant tumor in different patients or between tumor cells in different parts of the same patient), thereby escaping the body's immune response.
[0003] Chimeric antigen receptor T cell (CAR-T) therapy was born to address this problem. Specifically, the CAR molecule is an artificially designed and constructed receptor molecule, which is composed of a signal peptide, an extracellular antigen binding domain, a hinge region, a transmembrane region, a co-stimulatory domain, an intracellular signal transduction domain, etc. It has the functions of specifically recognizing tumor surface antigens, activating T cell killing activity, and stimulating T cell proliferation. By collecting T cells from tumor patients and artificially transducing the genes of CAR molecules, the patient's own T cells express CAR molecules to obtain CAR-T cells. After being re-infused into the patient's body, CAR-T cells can specifically and efficiently recognize and kill tumor cells through CAR molecules, achieving the effect of cancer treatment.
[0004] Since the concept of CAR-T therapy was first proposed in 1989, it has gone through three decades of development and multiple rounds of technological changes. The first-generation CAR-T cells are composed of only single-chain antibodies as extracellular antigen binding domains and CD3ζ as intracellular signal transduction domains. The first-generation CAR-T cells cannot fully activate the activity of T cells and have poor therapeutic effects. The second-generation CAR-T cells introduced a co-stimulatory domain on the basis of the first-generation CAR-T cells, which improved the in vitro proliferation ability and cytokine release level of T cells. The third-generation CAR-T cells added a co-stimulatory domain on the basis of the second-generation CAR-T cells. Although it can improve the killing activity of T cells, it may induce excessive release of cytokines and lead to serious side effects. Therefore, the new generation of CAR-T cells co-express other auxiliary factors on the basis of the second-generation CAR-T cells, such as the co-expression of IL-12 or the intracellular domains of certain cytokine receptors, which helps to improve tumor killing activity and safety.
[0005] However, the currently developed CAR-T cells have disadvantages such as low proliferation ability, increased exhaustion, low persistence, and high toxic side effects. Clinical studies have shown that in the treatment of solid cancers, due to the inhibitory tumor immune microenvironment, poor survival of immune cells and many other factors, anti-tumor drugs "fail" and cause tumor immune escape. Therefore, expressing auxiliary factors to promote the immune cell's ability to kill tumors while promoting its proliferation, prolonging survival time and improving memory ability is the key to improving the therapeutic effect of immune cells.
[0006] In summary, there is an urgent need in this field to develop more efficient and longer-lasting engineered immune cells targeting tumor cells, so that they can survive for a long time in the body and resist the inhibitory effects of the tumor microenvironment. Summary of the invention
[0007] The purpose of the present invention is to provide an engineered immune cell (such as CAR-T cells, TIL cells) that is more efficient and has better therapeutic effects for malignant tumors (especially solid tumors).
[0008] Another object of the present invention is to provide an engineered immune cell (such as CAR-T cell, TIL cell) that regulates IL-7 and TGFβ signaling pathways, and a preparation method and application thereof.
[0009] In a first aspect of the present invention, an engineered immune cell is provided, wherein the engineered immune cell is a T cell, a TIL cell, or a NK cell, and the immune cell has the following characteristics:
[0010] (a) the immune cells express exogenous IL-7 protein; and
[0011] (b) The immune cells express exogenous TGFβRII dominant inhibitory mutant protein or shRNA targeting endogenous TGFβRII transcripts.
[0012] In another preferred embodiment, the T cells include αβT cells, γδT cells, NKT cells, MAIT cells, or a combination thereof.
[0013] In another preferred embodiment, the engineered immune cells are selected from the following group:
[0014] (i) Chimeric antigen receptor T cells (CAR-T cells);
[0015] (ii) chimeric antigen receptor NK cells (CAR-NK cells);
[0016] (iii) Chimeric antigen receptor TIL cells (CAR-TIL cells).
[0017] In another preferred embodiment, the engineered immune cells are TIL cells.
[0018] In another preferred embodiment, the engineered immune cells are T cells from patients who have undergone radiotherapy and / or chemotherapy.
[0019] In another preferred embodiment, the engineered immune cells are autologous TIL cells from patients who have undergone radiotherapy and / or chemotherapy.
[0020] In another preferred embodiment, the engineered immune cells are autologous or allogeneic.
[0021] In another preferred embodiment, the IL-7 protein and / or TGFβRII dominant inhibitory mutant may be constitutively expressed or inducibly expressed.
[0022] In another preferred embodiment, the IL-7 protein is membrane-bound or secreted.
[0023] In another preferred embodiment, the TGFβRII dominant inhibitory mutant is membrane-bound.
[0024] In another preferred embodiment, the immune cell expresses a chimeric antigen receptor (CAR), wherein the CAR targets surface markers of tumor cells.
[0025] In another preferred embodiment, the CAR is constitutively expressed or inducibly expressed.
[0026] In another preferred embodiment, the structure of the IL-7 protein is as shown in Formula Z:
[0027] AH-TM-D (Z)
[0028] In the formula,
[0029] A is IL-7 protein, or an active fragment or a mutant thereof;
[0030] H is none or hinge region;
[0031] TM is none or transmembrane domain;
[0032] D is the absence or degradation domain (including the wild type, or its mutant / modified form); the "-" is a connecting peptide or peptide bond.
[0033] In another preferred embodiment, the A is a wild-type or mutant IL-7 protein of a human or non-human mammal.
[0034] In another preferred embodiment, the amino acid sequence of A is shown in SEQ ID No: 1.
[0035] In another preferred embodiment, the H is the hinge region of a protein selected from the group consisting of CD8, CD28, CD137, IgG, or a combination thereof.
[0036] In another preferred embodiment, the H is the hinge region of the CD8 protein.
[0037] In another preferred embodiment, the H is the hinge region of IgG protein Fc.
[0038] In another preferred embodiment, the amino acid sequence of H is shown in SEQ ID No: 2.
[0039] In another preferred embodiment, the TM is a transmembrane region of a protein selected from the following group: CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, CD278, CD152, CD279, CD233, CD314, or their mutants / modified forms, or their combinations.
[0040] In another preferred embodiment, the TM is the transmembrane region of CD8.
[0041] In another preferred embodiment, the amino acid sequence of the TM is shown in SEQ ID No: 3.
[0042] In another preferred embodiment, the D is an oxygen-dependent degradation domain (ODD) or a partial sequence thereof;
[0043] In another preferred embodiment, the amino acid sequence of ODD is shown in SEQ ID No:35.
[0044] In another preferred embodiment, the structures of the IL-7 protein and the TGFβRII dominant inhibitory mutant are as shown in Formula I:
[0045] Z0-Z1-Z2-D (I)
[0046] In the formula,
[0047] One of Z0 and Z2 is IL-7 protein, and the other is a dominant inhibitory mutant of TGFβRII;
[0048] Z1 is none or a connecting peptide;
[0049] D is the absence or degradation domain (including the wild type, or its mutant / modified form);
[0050] The "-" means nothing, a connecting peptide or a peptide bond.
[0051] In another preferred embodiment, Z0 is IL-7 protein, and Z2 is a dominant inhibitory mutant of TGFβRII.
[0052] In another preferred embodiment, the coding sequence of the IL-7 protein and the coding sequence of the TGFβRII dominant inhibitory mutant are connected through an internal ribosome entry site (IRES), a coding sequence of a 2A connecting peptide, or a coding sequence of a flexible connecting peptide.
[0053] In another preferred embodiment, the connecting peptide is selected from the following group: a 2A connecting peptide, or a flexible connecting peptide.
[0054] In another preferred embodiment, the 2A connecting peptide is P2A (SEQ ID No: 4) or T2A (SEQ ID No: 5).
[0055] In another preferred embodiment, the flexible connecting peptide is a connecting peptide composed of one or more G4S, such as 4×GGGGS (SEQ ID No: 6).
[0056] In another preferred embodiment, the nucleotide sequence of IRES is shown as SEQ ID No:7.
[0057] In another preferred example, the amino acid sequence of the IL-7 protein (Z0) is shown in SEQ ID No: 1 or SEQ ID No: 8.
[0058] In another preferred example, the amino acid sequence of the TGFβRII dominant inhibitory mutant (Z2) is shown in SEQ ID No: 9 or SEQ ID No: 34.
[0059] In another preferred embodiment, the shRNA targeting endogenous TGFβRII transcript inhibits the expression of endogenous TGFβRII transcript.
[0060] In another preferred embodiment, the TGFβRII dominant inhibitory mutant protein can be replaced by a shRNA expression frame targeting the endogenous TGFβRII transcript (SEQ ID No: 10).
[0061] In another preferred embodiment, the shRNA expression frame consists of a promoter and a shRNA coding sequence.
[0062] In another preferred embodiment, the promoter of the shRNA expression frame is U6 promoter (SEQ ID No: 11).
[0063] In another preferred embodiment, the binding site of the shRNA is located within 703-738 nt of the open reading frame of the TGFβRII gene (SEQ ID No: 12).
[0064] In another preferred example, the nucleotide sequence bound to the shRNA is shown as SEQ ID No:13, SEQ ID No:14, SEQ ID No:15, SEQ ID No:16 or SEQ ID No:17.
[0065] In another preferred example, the nucleotide sequence of the shRNA expression frame is shown as SEQ ID No: 18, SEQ ID No: 19, SEQ ID No: 20, SEQ ID No: 21 or SEQ ID No: 22.
[0066] In another preferred embodiment, the cell is a chimeric antigen receptor T cell (CAR-T cell), and the CAR-T cell has one or more of the following characteristics:
[0067] (a) the CAR-T cells express exogenous IL-7 protein;
[0068] (b) the CAR-T cells express exogenous TGFβRII dominant inhibitory mutant protein or shRNA targeting endogenous TGFβRII transcripts; and
[0069] (c) Optionally, the CAR-T cell expresses a chimeric antigen receptor CAR.
[0070] In another preferred embodiment, when the CAR-T cells are exposed to an inducer or induction condition, the CAR-T cells induce expression of CAR molecules and / or IL-7 and / or TGFβRII dominant inhibitory mutant proteins.
[0071] In another preferred embodiment, in the CAR-T cells, CAR, IL-7 and TGFβRII dominant inhibitory mutant proteins are expressed in series.
[0072] In another preferred embodiment, in the CAR-T cells, CAR, IL-7, TGFβRII dominant inhibitory mutant protein and shRNA targeting endogenous TGFβRII are expressed independently.
[0073] In another preferred embodiment, the "activation" refers to the binding of the CAR to the surface markers of tumor cells.
[0074] In another preferred embodiment, the "tumor surface marker" refers to a specific antigen on the surface of the tumor.
[0075] In another preferred embodiment, the chimeric antigen receptor CAR is located on the cell membrane of the engineered immune cell.
[0076] In another preferred embodiment, the chimeric antigen receptor CAR is located on the cell membrane of the CAR-T cell.
[0077] In another preferred embodiment, the IL-7 protein and / or TGFβRII dominant inhibitory mutant protein are localized on the cell membrane of the CAR-T cell.
[0078] In another preferred embodiment, the CAR targets surface markers of tumor cells, and the markers are selected from the following group: CD19, CD20, CD22, CD123, CD47, CD138, CD33, CD30, CD271, GUCY2C, CD24, CD133, CD44, CD166, CD276, ABCB5, ALDH1, mesothelin (MSLN), EGFR, GPC3, BCMA, ErbB2, NKG2D ligands, LMP1, EpCAM, VEGFR-1, Lewis-Y, ROR1, Claudin18.2, CEA, TAG-72, TROP2, CD147, CLDN6.
[0079] In another preferred embodiment, the structure of the CAR is as shown in Formula II:
[0080] L-scFv1-H-TM-C-CD3ζ-D(II)
[0081] In the formula,
[0082] L is none or a signal peptide sequence;
[0083] scFv1 is an antigen binding domain (such as an antibody or an active fragment thereof) that targets a surface marker of a tumor cell;
[0084] H is none or hinge region;
[0085] TM is the transmembrane domain;
[0086] C is the co-stimulatory signaling domain;
[0087] CD3ζ is a cytoplasmic signal transduction sequence derived from CD3ζ (including wild type, or mutant / modified form thereof);
[0088] D is the absence or degradation domain (including the wild type, or its mutant / modified form);
[0089] The "-" is a connecting peptide or a peptide bond.
[0090] In another preferred embodiment, the antigen binding domain (scFv1) is selected from the following group: single-chain antibody scFv, single-domain antibody VHH, the extracellular domain of a receptor protein, or a combination thereof.
[0091] In another preferred embodiment, the surface marker of the tumor cells is CD133 (SEQ ID No: 23) or CEA (SEQ ID No: 24).
[0092] In another preferred embodiment, the L is respectively selected from the signal peptides of the following proteins: CD8, GM-CSF, CD4, CD28, CD137, or mutants / modified forms thereof, or a combination thereof.
[0093] In another preferred embodiment, the amino acid sequence of L is shown in SEQ ID No:25.
[0094] In another preferred embodiment, the H is selected from the hinge region of the following proteins: CD8, CD28, CD137, IgG, or a combination thereof.
[0095] In another preferred embodiment, the H is selected from the following group: hinge region of IgG protein Fc or CD8.
[0096] In another preferred embodiment, the amino acid sequence of H is shown in SEQ ID No: 26 or SEQ ID No: 27.
[0097] In another preferred embodiment, the TM is selected from the transmembrane region of a protein in the following group: CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, CD278, CD152, CD279, CD233, CD314, or a mutant / modified form thereof, or a combination thereof.
[0098] In another preferred embodiment, the TM is the transmembrane region of CD8.
[0099] In another preferred embodiment, the amino acid sequence of the TM is shown in SEQ ID No: 3.
[0100] In another preferred embodiment, the C is selected from the co-stimulatory domain of the protein in the following group: OX40, CD2, CD7, CD27, CD28, CD30, CD40, CD70, CD134, 4-1BB (CD137), PD1, Dap10, CDS, ICAM-1, LFA-1 (CD11a / CD18), ICOS (CD278), NKG2D, GITR, OX40L, or its mutant / modified form, or a combination thereof.
[0101] In another preferred embodiment, C is a co-stimulatory domain derived from 4-1BB.
[0102] In another preferred embodiment, the amino acid sequence of C is shown in SEQ ID No:28.
[0103] In another preferred embodiment, the amino acid sequence of CD3ζ is shown in SEQ ID No:29.
[0104] In another preferred example, the amino acid sequence of the scFv1 is shown as SEQ ID NO:30 or SEQ ID NO:31 or SEQ ID NO:32.
[0105] In another preferred embodiment, in addition to the first CAR shown in Formula II, the CAR-T cell further contains a second CAR for targeting a second antigen, and the structure of the second CAR is shown in Formula III:
[0106] L-scFv2-H-TM-C-CD3ζ-D (III)
[0107] In the formula,
[0108] L is none or a signal peptide sequence;
[0109] scFv2 is an antigen binding domain (such as an antibody or an active fragment thereof) that targets a surface marker of a second tumor cell;
[0110] H is none or hinge region;
[0111] TM is the transmembrane domain;
[0112] C is the co-stimulatory domain;
[0113] CD3ζ is a cytoplasmic signaling sequence derived from CD3ζ or a mutant / modified form thereof;
[0114] D is the absence or degradation domain (including the wild type, or its mutant / modified form);
[0115] The "-" is a connecting peptide or a peptide bond.
[0116] In another preferred embodiment, the antigen binding domain (scFv2) is selected from the following group: single-chain antibody scFv, single-domain antibody VHH, the extracellular domain of a receptor protein, or a combination thereof.
[0117] In another preferred embodiment, the scFv2 in Formula III and the scFv1 in Formula II target different antigens.
[0118] In another preferred embodiment, the scFv2 is a single-chain variable region of an antibody or a single-domain antibody sequence and an active fragment thereof that targets a tumor antigen.
[0119] In another preferred embodiment, the scFv2 is an antibody single-chain variable region or a single-domain antibody sequence and its active fragment targeting an antigen selected from the following group: CD19, CD20, CD22, CD123, CD47, CD138, CD33, CD30, CD271, GUCY2C, CD24, CD133, CD44, CD166, CD276, ABCB5, ALDH1, mesothelin (MSLN), EGFR, GPC3, BCMA, ErbB2, NKG2D ligands, LMP1, EpCAM, VEGFR-1, Lewis-Y, ROR1, Claudin18.2, TROP2, CEA, TAG-72, CD147, CLDN6 or a combination thereof.
[0120] In another preferred embodiment, the first CAR shown in Formula II and the second CAR shown in Formula III can be combined into one to form a CAR shown in Formula IVa or IVb:
[0121] L-scFv1-scFv2-H-TM-C-CD3ζ-D (IVa)
[0122] L-scFv2-scFv1-H-TM-C-CD3ζ-D (IVb)
[0123] In the formula,
[0124] L is none or a signal peptide sequence;
[0125] scFv1 is an antibody or an active fragment thereof targeting a surface marker of a first tumor cell;
[0126] scFv2 is an antibody or an active fragment thereof that targets a surface marker of a second tumor cell;
[0127] H is none or hinge region;
[0128] TM is the transmembrane domain;
[0129] C is the co-stimulatory domain;
[0130] CD3ζ is a cytoplasmic signaling sequence derived from CD3ζ or a mutant / modified form thereof;
[0131] D is the absence or degradation domain (including the wild type, or its mutant / modified form);
[0132] The "-" is a connecting peptide or a peptide bond.
[0133] In a second aspect of the present invention, there is provided a method for preparing the engineered immune cell according to the first aspect of the present invention, comprising the following steps:
[0134] (A) providing an immune cell to be modified; and
[0135] (B) Transforming the immune cells so that the immune cells express exogenous IL-7 protein and exogenous TGFβRII dominant inhibitory mutant protein or shRNA targeting endogenous TGFβRII transcripts, thereby obtaining the engineered immune cells as described in the first aspect of the present invention.
[0136] In another preferred embodiment, in step (B), comprising:
[0137] (B1) introducing a first expression cassette expressing IL-7 into the immune cell;
[0138] (B2) introducing a second expression cassette expressing a dominant inhibitory mutant of TGFβRII or a shRNA targeting endogenous TGFβRII transcript into the immune cell;
[0139] The steps (B1) and (B2) can be performed in any order or in combination.
[0140] In another preferred embodiment, the step (B1) can be performed before, after, simultaneously with, or alternately with step (B2).
[0141] In another preferred embodiment, the step (B) further includes (B3) introducing a third expression cassette expressing the chimeric antigen receptor CAR into the immune cell; wherein the steps (B1), (B2), and (B3) can be performed in any order or combined.
[0142] In another preferred embodiment, the "combining" refers to combining two or three of the first expression cassette, the second expression cassette, and the optional third expression cassette into one expression cassette, and introducing the resultant into immune cells.
[0143] In another preferred embodiment, a method for preparing the CAR-immune cell is provided, comprising the following steps:
[0144] (A) providing an immune cell to be modified;
[0145] (B) Transforming the immune cells so that the immune cells express the CAR molecule as well as exogenous IL-7 protein and exogenous TGFβRII dominant inhibitory mutant protein or shRNA targeting endogenous TGFβRII transcripts, thereby obtaining the engineered immune cells as described in the first aspect of the present invention.
[0146] In another preferred embodiment, the immune cells are T cells, TIL cells, or NK cells.
[0147] In another preferred embodiment, in step (B), it includes: introducing a first expression cassette expressing IL-7, a second expression cassette expressing a dominant inhibitory mutant of TGFβRII or a shRNA targeting endogenous TGFβRII transcript, and an optional third expression cassette expressing the CAR into the immune cells; wherein the introduction steps can be performed in any order or in combination.
[0148] In another preferred embodiment, for any two expression cassettes among the first, second and third expression cassettes (taking the first expression cassette and the second expression cassette as an example), their transcription directions are in the same direction (→→), in opposite directions (→←) or in opposite directions (←→).
[0149] In another preferred embodiment, the first expression cassette, the second expression cassette and the third expression cassette are located on the same or different vectors.
[0150] In another preferred embodiment, the first expression cassette, the second expression cassette and the third expression cassette are located in the same vector.
[0151] In another preferred embodiment, when two or three of the CAR molecule, the exogenous IL-7 protein and the exogenous TGFβRII dominant inhibitory mutant protein are expressed in tandem, a connecting peptide or an IRES element is also included between the two proteins.
[0152] In another preferred embodiment, the connecting peptide is P2A or T2A or 4×GGGGS.
[0153] In another preferred embodiment, the vector is a viral vector, and preferably the viral vector contains the first, second and third expression cassettes in tandem.
[0154] In another preferred embodiment, the vector is selected from the following group: DNA, RNA, plasmid, lentiviral vector, adenoviral vector, retroviral vector, transposon, other gene transfer systems, or a combination thereof.
[0155] In another preferred embodiment, the vector is a pCDH series lentiviral vector.
[0156] In the third aspect of the present invention, a preparation is provided, which contains the engineered immune cells as described in the first aspect of the present invention, and a pharmaceutically acceptable carrier, diluent or excipient.
[0157] In another preferred embodiment, the preparation contains the CAR-T cells described in the present invention, and a pharmaceutically acceptable carrier, diluent or excipient.
[0158] In another preferred embodiment, the preparation is a liquid preparation.
[0159] In another preferred embodiment, the dosage form of the preparation includes injection.
[0160] In another preferred embodiment, the concentration of the engineered immune cells (such as CAR-T cells) in the preparation is 1×10 3 -1×10 8 cells / ml, preferably 1×10 4 -1×10 7 cells / ml.
[0161] In a fourth aspect of the present invention, there is provided a use of the engineered immune cells as described in the first aspect of the present invention for preparing a drug or preparation for preventing and / or treating cancer.
[0162] In another preferred embodiment, the use of the CAR-T cells and TIL cells as described in the first aspect of the present invention is provided for preparing a drug or preparation for preventing and / or treating cancer or tumors.
[0163] In another preferred embodiment, the preparation contains CAR-T cells and TIL cells, and a pharmaceutically acceptable carrier, diluent or excipient.
[0164] In another preferred embodiment, the tumor comprises a solid tumor.
[0165] In another preferred embodiment, the tumor is selected from the following group: colorectal cancer, gastric cancer, pancreatic cancer, esophageal cancer, breast cancer, ovarian cancer or liver cancer.
[0166] In a fifth aspect of the present invention, a kit for preparing the engineered immune cells according to the first aspect of the present invention is provided, the kit comprising a container, and:
[0167] (1) a first nucleic acid sequence comprising a first expression cassette for expressing IL-7; and
[0168] (2) A second nucleic acid sequence comprising a second expression cassette for expressing a dominant inhibitory mutant of TGFβRII or a shRNA targeting an endogenous TGFβRII transcript.
[0169] In another preferred embodiment, a kit for preparing the engineered immune cells according to the first aspect of the present invention is provided, wherein the kit comprises a container, and:
[0170] (1) a first nucleic acid sequence, wherein the first nucleic acid sequence comprises a first expression cassette for expressing IL-7;
[0171] (2) a second nucleic acid sequence comprising a second expression cassette for expressing a dominant inhibitory mutant of TGFβRII or a shRNA targeting an endogenous TGFβRII transcript; and
[0172] (3) an optional third nucleic acid sequence, wherein the third nucleic acid sequence contains a third expression cassette for expressing the CAR.
[0173] In another preferred embodiment, the first, second and third nucleic acid sequences are independent or connected.
[0174] In another preferred embodiment, the first, second and third nucleic acid sequences are located in the same or different containers.
[0175] In another preferred embodiment, the first, second and third nucleic acid sequences are located on the same or different vectors.
[0176] In another preferred embodiment, the first, second and third nucleic acid sequences are located in the same vector.
[0177] In another preferred embodiment, when two or three of the first, second and third nucleic acid sequences are located in the same vector, a coding sequence or an IRES element for expressing a connecting peptide is also included between two adjacent expression cassettes.
[0178] In another preferred embodiment, the connecting peptide is P2A or T2A or 4×GGGGS.
[0179] In another preferred embodiment, the vector is a viral vector, and preferably the viral vector contains the first, second and third nucleic acid sequences in tandem.
[0180] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS
[0181] Figure 1 The structural designs of the cofactors are shown.
[0182] Figure 2 The structural designs of the second-generation CAR and the fourth-generation CAR targeting CEA are shown.
[0183] Figure 3 The structural designs of the second-generation CAR and the fourth-generation CAR targeting CD133 are shown.
[0184] Figure 4 The expression rate of each auxiliary factor in flow cytometry-enhanced TIL cells is shown.
[0185] Figure 5 The secretion level of IL-7 in enhanced TIL cells is shown.
[0186] Figure 6The CAR molecule expression rate of CEA CAR-T cells was detected by flow cytometry.
[0187] Figure 7 The expression rate of dnTGFβRII in CEA CAR-T cells was detected by flow cytometry.
[0188] Figure 8 Detection of IL-7 secretion levels of CEA CAR-T cells is shown.
[0189] Fig. 9 The CAR molecule expression rate of CD133 CAR-T cells detected by flow cytometry is shown.
[0190] Fig.10 The expression rate of dnTGFβRII in CD133 CAR-T cells was detected by flow cytometry.
[0191] Fig.11 Detection of IL-7 secretion levels of CD133 CAR-T cells is shown.
[0192] Fig.12 The killing effect of enhanced TIL cells on liver cancer cells is shown.
[0193] Fig.13 The levels of IFN-γ release by enhanced TIL cells are shown.
[0194] Fig.14 The killing effect of CEA CAR-T cells co-expressing IL-7 and dnTGFβRII on HT55 is shown.
[0195] Fig.15 The killing effect of CD133 CAR-T cells co-expressing IL-7 and dnTGFβRII on SW620 is shown.
[0196] Fig.16 The in vivo tumor-suppressive effect of CD133 CAR-T cells co-expressing IL-7 and dnTGFβRII was shown.
[0197] Fig.17 The results showed that CAR-T cells expressing IL-7 and dnTGFβRII fusion protein have a killing effect on various solid tumor cells.
[0198] Fig.18 The in vitro proliferation ability of CAR-T cells co-expressing IL-7 and dnTGFβRII fusion protein was shown. DETAILED DESCRIPTION
[0199] After extensive and in-depth research and a large number of screenings, the inventors have for the first time simultaneously regulated the IL-7 and TGFβ pathways, that is, upregulated the IL-7 pathway and inhibited the TGFβ pathway, significantly improving the activation degree of the IL-7 signal of the engineered immune cells and significantly improving the resistance to the tumor microenvironment. Experiments have shown that the engineered immune cells of the present invention (taking TIL and CAR-T cells as examples) not only significantly improve the proliferation ability of immune cells, reduce exhaustion, and enhance resistance to the immunosuppressive microenvironment, but also unexpectedly reduce side effects compared to immune cells expressing IL-7×CCL19. The present invention was completed on this basis.
[0200] The present invention takes TIL and CAR-T cells as examples, and representatively describes the engineered immune cells of the present invention in detail. The engineered immune cells of the present invention are not limited to the TIL and CAR-T cells described in the context, and the engineered immune cells of the present invention have the same or similar technical features and beneficial effects as the TIL and CAR-T cells described in the context. Specifically, when immune cells express chimeric antigen receptor CAR, NK cells or TIL cells are equivalent to T cells (ie, T cells can be replaced by NK cells or TIL cells).
[0201] the term
[0202] In order that the present disclosure may be more readily understood, certain terms are first defined. As used in this application, unless otherwise expressly provided herein, each of the following terms shall have the meaning given below.
[0203] The term "about" can refer to a value or composition that is within an acceptable error range for the particular value or composition as determined by one of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined.
[0204] The terms "administer" or "administration" refer to introducing the product of the invention into a subject using any of a variety of methods and delivery systems known to those skilled in the art, including intravenous, intratumoral, intramuscular, subcutaneous, intraperitoneal, spinal or other parenteral routes of administration, such as by injection or infusion.
[0205] Antibody
[0206] As used herein, the term "antibody" (Ab) shall include, but is not limited to, immunoglobulins that specifically bind to an antigen and comprise at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds, or antigen-binding portions thereof. Each H chain comprises a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. The heavy chain constant region comprises three constant domains CH1, CH2, and CH3. Each light chain comprises a light chain variable region (abbreviated herein as VL) and a light chain constant region. The light chain constant region comprises one constant domain CL. The VH and VL regions can be further subdivided into hypervariable regions called complementary determining regions (CDRs), which are interspersed with more conservative regions called framework regions (FRs). Each VH and VL comprises three CDRs and four FRs, arranged in the following order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain binding domains that interact with antigens.
[0207] "Antibodies" also include single-domain antibodies (also called nanobodies). Single-domain antibodies are antibodies that are naturally missing light chains and exist in the peripheral blood of animals such as alpacas, camels, and sharks. The antibody contains only one heavy chain variable region (VHH) and two conventional CH2 and CH3 regions. The VHH structure cloned and expressed separately has the same structural stability and antigen binding activity as the original heavy chain antibody, and is the smallest unit known to bind to the target antigen.
[0208] Antigen binding domain
[0209] As used herein, "antigen binding domain" and "single-chain antibody fragment" all refer to Fab fragments, Fab' fragments, F(ab')2 fragments, single Fv fragments, or VHH fragments of single-domain antibodies that have antigen binding activity. Fv antibodies contain the variable region of the antibody heavy chain and the variable region of the light chain, but no constant region, and are the smallest antibody fragments with all antigen binding sites. Generally, Fv antibodies also contain a polypeptide linker between the VH and VL domains, and are able to form the structure required for antigen binding. The antigen binding domain is usually scFv (single-chain variable fragment). A single-chain antibody is preferably an amino acid chain sequence encoded by a nucleotide chain.
[0210] In addition, the immune cells of the present invention may also contain additional antibodies that specifically recognize antigens highly expressed in tumors, preferably single-chain antibodies, Fv antibodies, or single-domain antibodies.
[0211] Chimeric Antigen Receptor (CAR)
[0212] As used herein, chimeric immune antigen receptor (CAR) includes an extracellular domain, an optional hinge region, a transmembrane domain, and an intracellular domain. The extracellular domain includes an optional signal peptide and a target-specific binding domain (also referred to as an antigen binding domain). The intracellular domain includes a co-stimulatory domain and a CD3ζ chain portion. When CAR is expressed in T cells, the extracellular segment can recognize a specific antigen, and then the signal is transduced through the intracellular domain, causing cell activation proliferation, cytolytic toxicity, and secretion of cytokines such as IL-2 and IFN-γ, etc., affecting tumor cells, causing tumor cells to not grow, be prompted to die or otherwise be affected, and causing the patient's tumor load to shrink or be eliminated. The antigen binding domain is preferably fused with one or more intracellular domains from a co-stimulatory molecule and a CD3ζ chain. Preferably, the antigen binding domain is fused with the intracellular domain of a combination of a 4-1BB signaling domain and a CD3ζ signaling domain.
[0213] Chimeric Antigen Receptor T Cells (CAR-T Cells)
[0214] As used herein, the terms "CAR-T cells", "CAR-T", and "CAR-T cells of the present invention" all refer to the CAR-T cells described in the first aspect of the present invention.
[0215] CAR-T cells have the following advantages over other T-cell-based treatments: (1) The action of CAR-T cells is not restricted by MHC; (2) Since many tumor cells express the same tumor antigens, once the CAR gene construction targeting a certain tumor antigen is completed, it can be widely used; (3) CAR can utilize both tumor protein antigens and glycolipid non-protein antigens, expanding the target range of tumor antigens; (4) The use of the patient's own cells reduces the risk of rejection; and (5) CAR-T cells have immune memory function and can survive in the body for a long time.
[0216] In the immune cells of the present invention, the construct for activating the IL-7 pathway, the construct for inhibiting the TGFβ pathway, and the CAR molecule construct can be combined in various ways, representative methods include (but are not limited to): 2A peptide, flexible connecting peptide, IRES element, multiple promoters, co-transfection, co-transduction and the like.
[0217] Chimeric Antigen Receptor NK Cells (CAR-NK Cells)
[0218] As used herein, the terms "CAR-NK cell", "CAR-NK", and "CAR-NK cell of the present invention" all refer to the CAR-NK cell described in the first aspect of the present invention.
[0219] Natural killer (NK) cells are a major type of immune effector cells that protect the body from viral infection and tumor cell invasion through non-antigen specific pathways. Engineered (genetically modified) NK cells may acquire new functions, including the ability to specifically recognize tumor antigens and have enhanced anti-tumor cytotoxic effects.
[0220] Compared with autologous CAR-T cells, CAR-NK cells also have the following advantages, such as: (1) they directly kill tumor cells by releasing perforin and granzyme, but have no killing effect on normal cells in the body; (2) they release very small amounts of cytokines, thereby reducing the risk of cytokine storms; (3) they are very easy to expand in vitro and develop into "ready-made" products. Other than that, it is similar to CAR-T cell therapy.
[0221] TIL cells
[0222] In addition to CAR-T cell therapy, tumor infiltrating lymphocytes (TIL) therapy can also effectively identify and kill tumor cells to achieve the effect of cancer treatment.
[0223] TIL is an infiltrating immune cell that is isolated from tumor tissue and responds to tumor cells. These immune cells have the ability to recognize and attack tumor cells, and TIL cells are currently used to treat tumor patients. Compared with other immunotherapies, such as CAR-T cell therapy, TCR-T cell therapy, and PD-1 / PD-L1 immune checkpoint inhibitors, TIL therapy has the advantages of stronger specificity, higher safety, and low recurrence rate after treatment. However, the number of TIL cells in tumor tissue is small and their activity is usually suppressed by the immune microenvironment. In clinical treatment, a very large number of TIL cells must be prepared to obtain the ideal anti-tumor effect. Therefore, TIL therapy needs to be further optimized.
[0224] In the present invention, novel TIL cells with significantly improved performance were unexpectedly obtained by simultaneously activating the IL-7 pathway and inhibiting the TGFβ pathway in TIL cells.
[0225] IL-7
[0226] Human interleukin-7 (IL-7) is a pleiotropic cytokine with a wide range of immune effects. For a long time, the understanding of IL-7 has been focused on its effects on the growth, survival and differentiation of B cells and T cells. Exogenously injected IL-7 can enhance the body's anti-tumor immunity in vivo. The powerful immune effects of IL-7, especially its functions of regulating T cell proliferation, maintaining the stability of the intracellular environment, and enhancing T immune response, have made IL-7 increasingly popular as an immune regulatory factor.
[0227] In the present invention, the therapeutic effect of engineered immune cells is improved by activating the IL-7 pathway. Representative methods for activating the IL-7 pathway include (but are not limited to): expressing secretory or membrane-bound IL-7.
[0228] In the present invention, IL-7 can be fused with any structure that can be anchored on the cell membrane to express, thereby achieving the expression of membrane-bound IL-7.
[0229] In the present invention, the term "IL-7" includes wild-type and mutant IL-7 of humans and other mammals. It should be understood that the term also includes IL-7 analogs or IL-7 derivative proteins, as long as they have or retain the basic functions of wild-type IL-7.
[0230] TGF-β
[0231] Transforming growth factor-β (TGF-β) is a protein superfamily composed of structurally related multifunctional cytokines, including TGF-β1 / 2 / 3 subtypes, activins, bone morphogenetic proteins, and growth differentiation factors. TGF-β superfamily ligands regulate cell functions through seven type I TGF-β superfamily receptors (activin-like kinases-1 to 7) and five type II TGF-β superfamily receptors (TβRII, ActRII, ActRIIB, AMHRII, and BMPRII), playing an important role in embryonic development, tissue repair, and homeostasis of skeletal muscle, cardiovascular, nervous, endocrine, and immune systems.
[0232] TGF-β is a tumor-promoting factor that can induce epithelial-mesenchymal transition (EMT) of tumor cells and promote tumor cell invasion and metastasis. In addition, TGF-β is a key regulator of T cell responses and plays an important role in regulating immune responses. It can regulate the functions of almost every innate and adaptive immune cell, including dendritic cells, B cells, NK cells, innate lymphocytes, and granulocytes. In the late stage of tumors, most tumor cells can secrete TGF-β. Once the concentration of TGF-β increases, it can block the differentiation of immature T cells into Th1 cells and promote their transformation into Treg subsets. At the same time, it inhibits the antigen presentation function of dendritic cells, thereby leading to the immune escape of tumor cells.
[0233] In the present invention, representative methods of inhibiting the TGFβ pathway include, but are not limited to: overexpressing a dominant inhibitory mutant of the TGFβ receptor (dnTGFβRII) or an antibody to TGFβ, knocking down the TGFβ receptor by RNAi, and knocking out the TGFβ receptor by gene knockout (the TGFβ receptor includes TGFβRI and TGFβRII). A representative method of RNAi is to use shRNA targeting the endogenous TGFβRII transcript.
[0234] It should be understood that in the present invention, dnTGFβRII can be replaced by a TGFβR inhibitor (membrane-bound / secreted), an inhibitor of related proteins in the TGFβR signaling pathway / a means of interfering with the expression of related genes, knocking out or knocking down the TGFβ receptor TGFβRII in immune cells, or overexpressing its dominant inhibitory mutant dnTGFβRII, or overexpressing a membrane-bound TGFβ antibody.
[0235] TGFβRII dominant suppressor mutant (dnTGFβRII)
[0236] In the TGFβ signaling pathway, TGFβ initiates the transmission of related signals by binding to TGFβRI and TGFβRII. Specifically, after TGFβ binds to the extracellular domains of TGFβRI and TGFβRII, TGFβRI and TGFβRII can be spatially close to each other, and the intracellular domain of TGFβRII activates and phosphorylates the intracellular domain of TGFβRI, causing TGFβRI to exhibit kinase activity, thereby phosphorylating the transcription factor Smad and entering the nucleus to regulate the expression of downstream genes. dnTGFβRII is a mutant of the intracellular domain of TGFβRII that can still form a complex with TGFβ and TGFβRI through the extracellular domain, but cannot phosphorylate the intracellular domain of TGFβRI. Therefore, overexpressed dnTGFβRII can prevent endogenous TGFβRII from binding to TGFβ and TGFβRI or activating downstream Smads through competition, thereby achieving the effect of blocking the TGFβ signaling pathway.
[0237] In the present invention, by knocking down or knocking out the TGFβ receptor TGFβRII in immune cells, or overexpressing its dominant inhibitory mutant dnTGFβRII, the signaling pathway of endogenous TGFβRII can be effectively blocked, thereby reducing the inhibitory effect of TGFβ on immune cells, maintaining the activity of immune cells in the tumor microenvironment, and effectively improving the effect of tumor treatment.
[0238] Expression cassette
[0239] As used herein, "expression cassette" or "expression cassette of the present invention" includes a first expression cassette, a second expression cassette and a third expression cassette. The expression cassette of the present invention is as described in the fifth aspect of the present invention, wherein the first expression cassette expresses an exogenous IL-7 protein, the second expression cassette expresses an exogenous TGFβRII dominant inhibitory mutant protein, and the optional third expression cassette expresses the CAR.
[0240] In the present invention, the IL-7 protein, the TGFβRII dominant inhibitory mutant protein and the CAR molecule can be independently expressed constitutively or inducibly.
[0241] In the case of induced expression, when the CAR-T cell is activated by the corresponding inducer or the corresponding induction condition, the first expression cassette expresses the IL-7 protein, the second expression cassette expresses the TGFβRII dominant inhibitory mutant protein, and the third expression cassette expresses the CAR molecule. In this way, when the CAR-T cell of the present invention is not exposed to the corresponding inducer, the first expression cassette does not express the IL-7 protein, the second expression cassette does not express the TGFβRII dominant inhibitory mutant protein, and the third expression cassette does not express the CAR molecule.
[0242] In one embodiment, the first expression cassette, the second expression cassette and / or the third expression cassette further include a promoter and / or a terminator, respectively. The promoters of the first expression cassette, the second expression cassette and the third expression cassette may be constitutive or inducible promoters.
[0243] Carrier
[0244] The present invention also provides a vector containing the expression cassette of the present invention. Vectors derived from retroviruses such as lentiviruses are suitable tools for achieving long-term gene transfer because they allow transgenes to be stably integrated into the cell genome for a long time and replicate with the replication of the daughter cell genome. Lentivirus vectors have advantages over vectors derived from oncogenic retroviruses such as murine leukemia viruses because they can transduce non-proliferating cells and have the advantage of low immunogenicity.
[0245] Usually, expression cassette or nucleic acid sequence of the present invention can be connected to the promoter downstream by routine operation, and incorporated into expression vector.This vector can be integrated into the eukaryotic cell genome and replicated therewith.Typical cloning vectors include transcription and translation terminators, initial sequences and promoters that can be used to regulate the expression of the desired nucleic acid sequence.
[0246] The expression vectors of the present invention can also be used in standard gene delivery protocols for nucleic acid immunization and gene therapy. Methods of gene delivery are known in the art. See, for example, U.S. Patent Nos. 5,399,346, 5,580,859, 5,589,466, which are incorporated herein by reference in their entirety.
[0247] The expression cassette or nucleic acid sequence can be cloned into many types of vectors. For example, the expression cassette or nucleic acid sequence can be cloned into such vectors, which include but are not limited to plasmids, phagemids, phage derivatives, animal viruses and cosmids. Specific vectors of interest include expression vectors, replication vectors, etc.
[0248] Further, expression vector can be provided to cell in the form of viral vector. Viral vector technology is well known in the art and is described in, for example, Molecular Cloning: A Laboratory Manual (Sambrook et al., Cold Spring Harbor Laboratory, New York, 2001) and other virology and molecular biology manuals. The virus that can be used as a vector includes but is not limited to retrovirus, adenovirus, adeno-associated virus, herpes virus and slow virus. Generally, suitable vectors include at least one replication origin, promoter sequence, convenient restriction enzyme site and one or more selectable markers (for example, WO01 / 96584; WO01 / 29058; and U.S. Patent number 6,326,193) that work in organisms.
[0249] Many virus-based systems have been developed and used for gene transduction of mammalian cells. For example, retroviruses provide a convenient platform for gene delivery systems. The selected gene can be inserted into a vector and packaged into retroviral particles using techniques known in the art. The recombinant virus can then be isolated and delivered to a subject's cells in vivo or in vitro. Many retroviral systems are known in the art. In one embodiment, a lentiviral vector is used. Many DNA viral systems are known in the art. In some embodiments, an adenoviral vector is used. Many adenoviral vectors are known in the art.
[0250] Additional promoter elements, such as enhancers, can regulate the frequency of transcription initiation. Typically, these elements are located in the 30-110bp region upstream of the start site, although recently many promoters have been shown to also contain functional elements downstream of the start site. The intervals between promoter elements are often flexible, so that when an element is inverted or moved relative to another element, the promoter function is maintained. In the thymidine kinase (tk) promoter, the intervals between promoter elements can be increased by 50bp, and activity begins to decline. Depending on the promoter, it is shown that a single element can work cooperatively or independently to start transcription.
[0251] An example of a suitable promoter is a cytomegalovirus (CMV) promoter sequence. This promoter sequence is a strong constitutive promoter sequence that can drive any polynucleotide sequence operably connected thereto to express at a high level. Another example of a suitable promoter is elongation growth factor-1α (EF-1α). However, other constitutive promoter sequences may also be used, including but not limited to simian virus 40 (SV40) early promoter, mouse mammary tumor virus (MMTV), human immunodeficiency virus (HIV) long terminal repeat (LTR) promoter, MoMuLV promoter, avian leukemia virus promoter, Epstein-Barr virus (Epstein-Barr virus, EBV) immediate early promoter, Rous sarcoma virus promoter, and human gene promoter, such as but not limited to actin promoter, myosin promoter, heme promoter, and creatine kinase promoter. Further, the present invention should not be limited to the application of constitutive promoters. Inducible promoters are also considered to be a part of the present invention. The use of an inducible promoter provides a molecular switch that can turn on the expression of a polynucleotide sequence connected to the inducible promoter when desired, or turn off expression when not desired. Examples of inducible promoters include, but are not limited to, metallothionein promoters, glucocorticoid promoters, progesterone promoters, and tetracycline promoters.
[0252] The expression vector introduced into the cell may also comprise any one or both of a selectable marker gene or a reporter gene, so that the expression cell can be identified and selected from a transfected or infected cell population by a viral vector. In other respects, selectable markers may be carried on a single section of DNA and used for cotransfection procedures. Both selectable marker genes and reporter genes may be flanked by suitable regulatory sequences so that they can be expressed in host cells. Useful selectable marker genes include, for example, antibiotic resistance genes, such as neomycin, etc.
[0253] Methods for introducing genes into cells and expressing genes into cells are known in the art. In the context of expression vectors, vectors can be easily introduced into host cells, for example, mammals (such as human T cells), bacteria, yeast or insect cells, by any method known in the art. For example, expression vectors can be transferred into host cells by physical, chemical or biological means.
[0254] Physical methods for introducing polynucleotides into host cells include calcium phosphate precipitation, cationic complex transfection, lipofection, particle bombardment, microinjection, electroporation, and the like. Methods for producing cells containing vectors and / or exogenous nucleic acids are well known in the art. See, for example, Molecular Cloning: A Laboratory Manual (Sambrook et al., Cold Spring Harbor Laboratory, New York, 2001). Preferred methods for introducing polynucleotides into host cells are liposome transfection and cationic complex polyethyleneimine transfection.
[0255] Biological methods for introducing polynucleotides into host cells include the use of DNA and RNA vectors. Viral vectors, particularly retroviral vectors, have become the most widely used methods for inserting genes into mammalian cells such as human cells. Other viral vectors can be derived from lentiviruses, poxviruses, herpes simplex virus I, adenoviruses, and adeno-associated viruses, etc. See, for example, U.S. Patent Nos. 5,350,674 and 5,585,362.
[0256] Chemical means for introducing polynucleotides into host cells include colloidal dispersion systems, such as macromolecular complexes, nanocapsules, microspheres, beads; and lipid-based systems, including oil-in-water emulsions, micelles, mixed micelles and liposomes. An exemplary colloidal system used as a delivery vehicle in vitro and in vivo is a liposome (e.g., an artificial membrane vesicle).
[0257] In the case of using a non-viral delivery system, an exemplary delivery vehicle is a liposome. Consider using lipid formulations to introduce nucleic acid into a host cell (in vitro, ex vivo or in vivo). On the other hand, the nucleic acid can be associated with a lipid. The nucleic acid associated with a lipid can be encapsulated in the aqueous interior of the liposome, dispersed in the lipid bilayer of the liposome, attached to the liposome through a connecting molecule associated with both the liposome and the oligonucleotide, trapped in the liposome, compounded with the liposome, dispersed in a solution comprising lipid, mixed with lipid, combined with lipid, included in lipid as a suspension, included in micelle or compounded with micelle, or otherwise associated with lipid. The lipid, lipid / DNA or lipid / expression vector associated with the composition are not limited to any specific structure in the solution. They can also be simply dispersed in the solution, and may form an aggregate of size or shape inhomogeneity. Lipid is a lipid substance, which can be a naturally occurring or synthetic lipid. For example, lipids include fat droplets that occur naturally in the cytoplasm as well as compounds that contain long-chain aliphatic hydrocarbons and their derivatives such as fatty acids, alcohols, amines, amino alcohols, and aldehydes.
[0258] In a preferred embodiment of the present invention, the vector is a lentiviral vector.
[0259] It should be understood that in the present invention, in addition to using multiple lentiviruses for transduction, direct transfection of mRNA or plasmids, or expression of artificial transcription factors, etc. can also be used to jointly express IL-7 and TGFβRII dominant inhibitory mutant molecules or shRNA targeting endogenous TGFβRII transcripts in immune cells such as T cells and TIL cells.
[0260] preparation
[0261] The present invention provides a preparation containing the engineered immune cells (such as CAR-T cells) described in the first aspect of the present invention, and a pharmaceutically acceptable carrier, diluent or excipient. In one embodiment, the preparation is a liquid preparation. Preferably, the preparation is an injection. Preferably, the concentration of the immune cells (such as TIL cells or CAR-T cells) in the preparation is 1×10 3 -1×10 8 cells / ml, preferably 1×10 4 -1×10 7 cells / ml.
[0262] In one embodiment, the formulation may include a buffer such as neutral buffered saline, sulfate buffered saline, etc.; a carbohydrate such as glucose, mannose, sucrose or dextran, mannitol; a protein; a polypeptide or an amino acid such as glycine; an antioxidant; a chelating agent such as EDTA or glutathione; an adjuvant (e.g., aluminum hydroxide); and a preservative. The formulation of the present invention is preferably formulated for intravenous administration.
[0263] Therapeutic applications
[0264] The present invention provides therapeutic applications of cells (e.g., T cells and TIL cells, etc.) transduced with a vector (e.g., a lentiviral vector) containing the expression cassette of the present invention. The transduced T cells or TIL cells can target surface markers of tumor cells and express IL-7 and TGFβRII dominant inhibitory mutant proteins, thereby synergistically and significantly improving their tumor cell killing efficiency.
[0265] Therefore, the present invention also provides a method for stimulating an immune response mediated by T cells or TIL cells targeting a mammalian tumor cell population or tissue, comprising the following steps: administering the CAR-T cells of the present invention or administering the enhanced TIL cells of the present invention to a mammal.
[0266] In one embodiment, the present invention provides a type of cell therapy in which the patient's autologous T cells (or allogeneic donors) are isolated, activated and genetically modified to produce CAR-T cells, which are then injected into the same patient. This approach makes the probability of graft-versus-host reaction extremely low, and the antigen is recognized by the T cells in an MHC-free manner. In addition, CAR-T can treat a variety of different cancers that express the antigen. Unlike antibody therapy, CAR-T cells can replicate in vivo, producing long-term persistence that can lead to sustained tumor control.
[0267] In one embodiment, the present invention provides a type of cell therapy in which the patient's autologous TIL cells (or allogeneic donors) are isolated, activated and genetically modified to produce enhanced TIL cells, which are then injected into the same patient. This approach makes the probability of occurrence of risks such as graft-versus-host reaction, cytokine storm, off-target, and tumor cell immune escape extremely low, and tumor cells are accurately recognized by TIL cells. Unlike antibody therapy, TIL cells can replicate in vivo, producing long-term persistence that can lead to sustained tumor control.
[0268] In one embodiment, the CAR-T cells or enhanced TIL cells of the present invention can undergo stable in vivo expansion and can last for months to years. In addition, the CAR-mediated immune response can be part of an adoptive immunotherapy step, in which the CAR-T cells can induce a specific immune response to tumor cells that highly express the antigen recognized by the CAR antigen binding domain.
[0269] Treatable cancers include tumors that are not vascularized or substantially not vascularized, as well as vascularized tumors. The types of cancers treated with the CAR of the present invention include, but are not limited to, colorectal cancer, breast cancer, liver cancer, pancreatic cancer, gastric cancer, esophageal cancer, ovarian cancer, etc.
[0270] Generally, cells activated and expanded as described herein can be used to treat and prevent diseases such as tumors. Therefore, the present invention provides a method for treating cancer, which comprises administering to a subject in need thereof a therapeutically effective amount of CAR-T cells or enhanced TIL cells of the present invention.
[0271] The CAR-T cells and enhanced TIL cells of the present invention can be administered alone, or as a pharmaceutical composition with a diluent and / or in combination with other components such as IL-2, IL-17, IL-7, IL-15, IL-21 or other cytokines or cell groups. In short, the pharmaceutical composition of the present invention may include a target cell population as described herein, in combination with one or more pharmaceutically or physiologically acceptable carriers, diluents or excipients.
[0272] The pharmaceutical composition of the present invention can be administered in a manner suitable for the disease to be treated (or prevented). The amount and frequency of administration will be determined by factors such as the patient's condition, and the type and severity of the patient's disease, or can be determined by clinical trials.
[0273] When "therapeutically effective amount", "anti-tumor effective amount", "tumor-inhibitory effective amount" or "therapeutic amount" is indicated, the exact amount of the composition of the present invention to be administered can be determined by a physician, taking into account individual differences in the patient's (subject's) age, weight, tumor size, degree of infection or metastasis, and condition. The pharmaceutical composition comprising the T cells or enhanced TIL cells described herein can be administered in an amount of 10 4 Up to 10 11 The dosage is preferably 10 cells / kg body weight. 5 Up to 10 8 The T cell composition can also be administered multiple times at these doses. The cells can be administered using well-known infusion techniques in immunotherapy (see, e.g., Rosenberg et al., New Eng. J. of Med. 319:1676, 1988). The optimal dose and treatment regimen for a specific patient can be easily determined by a medical technician by monitoring the patient's disease signs and adjusting the treatment accordingly.
[0274] The administration of the subject composition can be carried out in any convenient manner, including by spraying, injection, swallowing, infusion, implantation or transplantation. The composition described herein can be administered to the patient subcutaneously, intradermally, intratumorally, intranode, intraspinal, intramuscularly, by intravenous injection or intraperitoneal administration. In one embodiment, the T cell or enhanced TIL cell composition of the present invention is administered to the patient by intradermal or subcutaneous injection. In another embodiment, the T cell or enhanced TIL cell composition of the present invention is preferably administered by intravenous injection. The composition of T cell or enhanced TIL cell can be directly injected into a tumor, a lymph node or an infection site.
[0275] In certain embodiments of the invention, cells activated and expanded using the methods described herein or other methods known in the art to expand T cells to therapeutic levels are administered to patients in combination with any number of related treatment forms (e.g., before, simultaneously or after), including but not limited to treatment with the following agents: agents such as antiviral therapy, cidofovir and interleukin-2, cytarabine (ARA-C) or natalizumab treatment for MS patients or efavirenz treatment for psoriasis patients or other treatments for PML patients. In further embodiments, the T cells or enhanced TIL cells of the present invention can be used in combination with chemotherapy, radiation, immunosuppressants such as cyclosporine, azathioprine, methotrexate, mycophenolate and FK506, antibodies or other immunotherapeutic agents. In further embodiments, the cell compositions of the present invention are administered to patients in combination with bone marrow transplantation, chemotherapeutic agents such as fludarabine, external beam radiation therapy (XRT), cyclophosphamide (e.g., before, simultaneously or after). For example, in one embodiment, the subject may undergo standard treatment with high-dose chemotherapy followed by a peripheral blood stem cell transplant. In some embodiments, after the transplant, the subject receives an infusion of the expanded immune cells of the invention. In an additional embodiment, the expanded cells are administered before or after surgery.
[0276] The dosage of the above treatments administered to a patient will vary with the precise nature of the condition being treated and the recipient of the treatment. The dosage ratio for human administration can be implemented according to practices accepted in the art. Typically, 1×10 5 to 1×10 12 The modified T cells or enhanced TIL cells of the present invention are administered to the patient, for example, by intravenous infusion.
[0277] Main advantages of the present invention
[0278] (1) The combination of simultaneously activating the IL-7 pathway and inhibiting the TGFβ pathway can be applied to a variety of different immune cells, such as TIL, CAR-T, TCR-T, NK and other immune cells.
[0279] (2) The modification of the present invention that activates the IL-7 pathway and inhibits the TGFβ pathway unexpectedly improves the function of TIL cells to a greater extent than that of T cells. The CAR-TIL cells (or enhanced TIL cells) of the present invention have a significantly more efficient ability to kill tumor cells.
[0280] (3) Unexpectedly, when engineered immune cells are prepared using T cells or TIL cells from patients who have undergone radiotherapy and / or chemotherapy (these cells are often unsuitable for preparing engineered immune cells due to decreased immune capacity or high degree of exhaustion), the strategy of activating the IL-7 pathway and inhibiting the TGFβ pathway of the present invention results in a higher degree of functional improvement compared to T cells from healthy donors.
[0281] (4) The application of the CAR immune cells of the present invention in the treatment of solid tumors has great potential, especially in the treatment of colorectal cancer, ovarian cancer, breast cancer, liver cancer, pancreatic cancer, gastric cancer, esophageal cancer, etc.
[0282] (5) Compared with CAR-T cells that only express dnTGFβRII or TGFβRII-IL-7RA fusion protein, the present invention can synergistically further improve the proliferation ability of CAR-T cells, the release level of IFN-γ and the killing effect on tumors.
[0283] (6) Compared with CAR-T cells that jointly express IL-7 and CCL19, the engineered immune cells of the present invention can improve the killing effect of CAR-T cells on tumor cells that highly express TGFβ in vivo and in vitro, and unexpectedly reduce toxic side effects.
[0284] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are usually carried out under conventional conditions, such as the conditions described in "Molecular Cloning: A Laboratory Manual" (Sambrook et al., New York: Cold Spring Harbor Laboratory Press, 1989), or according to the conditions recommended by the manufacturer. Unless otherwise stated, percentages and parts are weight percentages and weight parts.
[0285] Unless otherwise stated, the reagents and materials used in the examples were commercially available.
[0286] Materials and Methods
[0287] Structural design of auxiliary factors and CAR molecules
[0288] The structural design of each auxiliary factor is as follows Figure 1 shown.
[0289] (1) BW7TG is composed of the following structures in series: IL-7, self-cleaving peptide P2A (P2A for short), and TGFβRII dominant inhibitory mutant (dnTGFβRII for short).
[0290] (2) BW197-2 is composed of the following structures in series: IL-7, self-cleaving peptide T2A (abbreviated as T2A), CCL19, P2A, and enhanced green fluorescent protein (abbreviated as eGFP).
[0291] (3) BWTG is composed of the following structures in series: dnTGFβRII.
[0292] The structural design of CAR molecules targeting CEA is as follows Figure 2 shown.
[0293] (1) BC001 is composed of the following structures in series: human CD8 signal peptide [abbreviated as CD8(SP)], anti-human CEA single-chain antibody (abbreviated as CEA scFv), human CD8 hinge region [abbreviated as CD8(hinge)], human CD8 transmembrane domain [abbreviated as CD8(TM)], human 4-1BB intracellular co-stimulatory domain [abbreviated as 4-1BB(ID)], and human CD3ζ intracellular signal transduction domain [abbreviated as CD3ζ(ID)].
[0294] (2) BC010 is composed of the following structures in series: CD8 (SP), CEA scFv, CD8 (hinge), CD8 (TM), 4-1BB (ID), CD3ζ (ID), self-cleaving peptide F2A (abbreviated as F2A), IL-7, T2A, and CCL19.
[0295] (3) BC011 is composed of the following structures in series: CD8 (SP), CEA scFv, CD8 (hinge), CD8 (TM), 4-1BB (ID), CD3ζ (ID), F2A, IL-7, P2A, and dnTGFβRII.
[0296] The structural design of CAR molecules targeting CD133 is as follows Figure 3 shown.
[0297] (1) BW133-2 is composed of the following structures in series: CD8 (SP), CD133 scFv, human IgG hinge region [abbreviated as IgG (Fc)], CD8 (TM), 4-1BB (ID), and CD3ζ (ID).
[0298] (2) BW133-12 is composed of the following structures in series: IL-7, T2A, CCL19, F2A, CD8 (SP), CD133scFv, IgG (Fc), CD8 (TM), 4-1BB (ID), and CD3ζ (ID).
[0299] (3) BW133-13 is composed of the following structures in series: IL-7, P2A, dnTGFβRII, F2A, CD8 (SP), CD133 scFv, IgG (Fc), CD8 (TM), 4-1BB (ID), and CD3ζ (ID).
[0300] (4) BW133-11B is composed of the following structures in series: CD8 (SP), CD133 scFv, IgG (Fc), CD8 (TM), 4-1BB (ID), CD3ζ (ID), internal ribosome entry site (IRES), and dnTGFβRII.
[0301] (5) BW133-6B is composed of the following structures in series: CD8 (SP), CD133 scFv, IgG (Fc), CD8 (TM), 4-1BB (ID), CD3ζ (ID), IRES, IL-7, T2A, and CCL19.
[0302] (6) BW133-7B is composed of the following structures in series: CD8 (SP), CD133 scFv, IgG (Fc), CD8 (TM), 4-1BB (ID), CD3ζ (ID), IRES, IL-7, P2A, and dnTGFβRII.
[0303] (7) BW133-7E is composed of the following structures in series: CD8 (SP), CD133 scFv, IgG (Fc), CD8 (TM), 4-1BB (ID), CD3ζ (ID), IRES, and a fusion protein of IL-7 and dnTGFβRII (abbreviated as IL-7:dnTGFβRII).
[0304] The amino acid sequence of the relevant structure is as follows:
[0305] human IL-7 (SEQ ID No: 1):
[0306]
[0307] CD8 hinge 1 (SEQ ID No: 2):
[0308]
[0309] CD8 TM (SEQ ID No: 3):
[0310]
[0311] P2A (SEQ ID No: 4):
[0312]
[0313] T2A (SEQ ID No: 5):
[0314]
[0315] 4×GGGGS (SEQ ID No: 6):
[0316]
[0317] IRES (SEQ ID No: 7):
[0318]
[0319] mIL-7 (SEQ ID No: 8):
[0320]
[0321] TGFβRII dominant inhibitory mutant 1 (SEQ ID No: 9):
[0322]
[0323] TGFβRII mRNA (SEQ ID No:10):
[0324]
[0325]
[0326] U6 promoter nucleotide sequence (SEQ ID No: 11):
[0327]
[0328] TGFβRII shRNA targeting range nucleotide sequence (SEQ ID No: 12):
[0329]
[0330] TGFβRII shRNA binding site nucleotide sequence 1 (SEQ ID No: 13):
[0331]
[0332] TGFβRII shRNA binding site nucleotide sequence 2 (SEQ ID No: 14):
[0333]
[0334] TGFβRII shRNA binding site nucleotide sequence 3 (SEQ ID No: 15):
[0335]
[0336] TGFβRII shRNA binding site nucleotide sequence 4 (SEQ ID No: 16):
[0337]
[0338] TGFβRII shRNA binding site nucleotide sequence 5 (SEQ ID No: 17):
[0339]
[0340] TGFβRII shRNA expression cassette nucleotide sequence 1 (SEQ ID No: 18):
[0341]
[0342] TGFβRII shRNA expression cassette nucleotide sequence 2 (SEQ ID No: 19):
[0343]
[0344] TGFβRII shRNA expression cassette nucleotide sequence 3 (SEQ ID No: 20):
[0345]
[0346] TGFβRII shRNA expression cassette nucleotide sequence 4 (SEQ ID No: 21):
[0347]
[0348] TGFβRII shRNA expression cassette nucleotide sequence 5 (SEQ ID No: 22):
[0349]
[0350] CD133 (SEQ ID No: 23):
[0351]
[0352] CEA (SEQ ID No: 24):
[0353]
[0354] CD8 signal peptide(SEQ ID No:25):
[0355]
[0356] IgG hinge (SEQ ID No: 26):
[0357]
[0358] CD8 hinge 2 (SEQ ID No: 27):
[0359]
[0360] 4-1BB co-stimulatory domain (SEQ ID No: 28):
[0361]
[0362] CD3ζ intracellular domain (SEQ ID No: 29):
[0363]
[0364] CD133 scFv-1 (SEQ ID No: 30):
[0365]
[0366] CD133 scFv-2 (SEQ ID No. 31):
[0367]
[0368] CEA scFv (SEQ ID No: 32):
[0369]
[0370] IL7:dnTGFβRII (SEQ ID No:33):
[0371]
[0372] TGFβRII dominant inhibitory mutant 2 (SEQ ID No: 34):
[0373]
[0374] ODD (SEQ ID: 35):
[0375]
[0376] Example 1 Preparation of Lentivirus Vector
[0377] The target gene fragments were constructed into the lentiviral expression vector pCDH-EF1α-MCS, and then the vector plasmids were mixed with the lentiviral packaging plasmids pMDLg-pRRE, pRSV-Rev and pMD2.G, and transfected into 293T cells using Lipofectamine 3000 reagent according to the instructions. The culture medium was replaced with complete medium 6 hours after transfection.
[0378] The virus supernatants were collected 48h and 72h after transfection to obtain virus concentrates, which were named BW7TG, BW197-2, BWTG, BC001, BC010, BC011, BW133-2, BW133-12, BW133-13, BW133-11B, BW133-6B, BW133-7B, and BW133-7E. The collected virus concentrates were stored at -80°C.
[0379] Finally, Jurkat cells were used as materials to detect the activity titer of the above lentivirus.
[0380] Example 2 Preparation and Detection of Enhanced TIL Cells
[0381] (1) Preparation of enhanced TIL cells
[0382] The single cell suspension obtained after digestion of the tumor tissue was cultured in a medium containing anti-human CD3 antibody and IL-2 until the TIL cells entered the logarithmic growth phase. The above-mentioned lentiviral vectors were added at an MOI of 10 IU / ml, and the medium was replaced with X-VIVO 15 complete medium 72 hours after infection. The enhanced TIL cells obtained were named BW7TG TIL, BW197-2 TIL, and BWTG TIL using the name of the lentivirus, and the T cells not transduced with the lentivirus were named Ctrl TIL.
[0383] (2) Transduction efficiency and IL-7 expression detection of enhanced TIL cells
[0384] The cells to be tested were washed twice with PBS and resuspended in FACS buffer. According to the antibody instructions, BV421-labeled anti-human CD3 antibody and APC-labeled anti-human TGFβRⅡ antibody were added to the cell suspension to be tested, incubated at 4°C for 60 minutes, and TIL cells not transfected with lentivirus were used as negative controls. The expression rates of dnTGFβRII and eGFP in TIL cells were detected by flow cytometry to characterize the transduction efficiency. FlowJo software was used for analysis.
[0385] The results are as follows Figure 4 As shown, the expression rate of BW7TG in TIL cells was 67.0%, the expression rate of BWTG in TIL cells was 51.7%, and the expression rate of BW197-2 in TIL was 30.8%, indicating that dnTGFβRII can be effectively expressed in TIL cells.
[0386] Use X-VIVO 15 medium to adjust the TIL cells to 1×10 5 / well. After 96 hours of culture, centrifuge and aspirate the supernatant of the co-cultured cells, and dilute the sample with PBS containing 1% BSA. At the same time, dissolve the IL-7 standard with ddH2O and dilute the standard according to the recommended gradient ratio. Add the standard and experimental samples to the reaction wells coated with IL-7 capture antibody, 100μl per well. After incubation at room temperature for 1 to 3 hours, prepare 1× cleaning solution and wash each well with 300μl cleaning solution 3 times. After patting the liquid in the well dry, add 100μl enzyme-labeled IL-7 detection antibody to each well and incubate at room temperature for 1 to 3 hours. Wash each well with 300μl cleaning solution 3 times. After patting the liquid in the well dry, add 100μl color substrate. After incubation at room temperature in the dark for 20 minutes, add 50μl stop solution to each well, measure the absorbance at 450nm with an enzyme reader and calculate the concentration of IL-7.
[0387] The results are as follows Figure 5 As shown, the IL-7 secretion level of Ctrl TIL was 0.8±0.2pg / ml, that of BW7TG TIL was 8604.6±1003.8pg / ml, that of BWTG was 1.4±0.1pg / ml, and that of BW197-2 was 1486.2±242.3pg / ml, indicating that IL-7 can be effectively expressed and secreted in TIL cells.
[0388] Example 3 Preparation and detection of CAR-T cells
[0389] (1) Preparation of CAR-T cells
[0390] Peripheral blood mononuclear cells (PBMC) from healthy donors were resuscitated in AIM V medium and cultured with anti-human CD3 / CD28 antibodies. The above cells were transduced with lentivirus at an MOI of 5 IU / ml. On the 7th day after transduction, the expression of the corresponding CAR molecules was detected. On the 10th day after transduction, the cells were collected and stored in liquid nitrogen for later use. The obtained CAR-T cells followed the name of the lentivirus and were named BC001, BC010, BC011, BW133-2, BW133-12, BW133-13, BW133-11B, BW133-6B, BW133-7B, BW133-7E, and the T cells not transduced with lentivirus were named Ctrl T.
[0391] (2) Detection of CAR molecules, dnTGFβRII and IL-7 expression in CEA CAR-T cells
[0392] The Ctrl T, BC001, BC010 and BC011 cells to be tested were washed twice with PBS and resuspended with FACS buffer. According to the antibody instructions, PE-labeled CEA protein and BV421-labeled anti-human CD3 antibody were added to the cell suspension to be tested and incubated at 4°C for 60 minutes. The expression rate of CEA CAR molecules in Ctrl T, BC001, BC010 and BC011 cells was detected by flow cytometry.
[0393] The results are as follows Figure 6 As shown, the expression rates of CAR molecules in BC001, BC010 and BC011 cells were 80.8%, 88.1% and 86.5%, respectively.
[0394] The Ctrl T and BC011 cells to be tested were washed twice with PBS and resuspended in FACS buffer. According to the antibody instructions, BV421-labeled anti-human CD3 antibody and APC-labeled anti-human TGFβRⅡ antibody were added to the cell suspension to be tested, incubated at 4°C for 60 minutes, and Ctrl T cells not transfected with lentivirus were used as negative controls. The expression rate of dnTGFβRII in Ctrl T and BC011 cells was detected by flow cytometry. FlowJo software was used for analysis.
[0395] The results are as follows Figure 7 As shown, the expression rate of dnTGFβRII in BC011 cells was 34.2%, indicating that BC011 cells successfully expressed dnTGFβRII molecules.
[0396] Use AIM V medium to adjust the T cells to 1×10 5 / well. After 96 hours of culture, centrifuge and aspirate the supernatant of the co-cultured cells, and dilute the sample with PBS containing 1% BSA. At the same time, dissolve the IL-7 standard with ddH2O and dilute the standard according to the recommended gradient ratio. Add the standard and experimental samples to the reaction wells coated with IL-7 capture antibody, 100μl per well. After incubation at room temperature for 1 to 3 hours, prepare 1× cleaning solution and wash each well with 300μl cleaning solution 3 times. After patting the liquid in the well dry, add 100μl enzyme-labeled IL-7 detection antibody to each well and incubate at room temperature for 1 to 3 hours. Wash each well with 300μl cleaning solution 3 times. After patting the liquid in the well dry, add 100μl color substrate. After incubation at room temperature in the dark for 20 minutes, add 50μl stop solution to each well, measure the absorbance at 450nm with an enzyme reader and calculate the concentration of IL-7.
[0397] The results are as follows Figure 8 As shown, the IL-7 secretion levels of Ctrl T and BC001 cells were 0.0±0.0pg / ml and 0.4±0.0pg / ml. In comparison, the IL-7 secretion levels of BC010 and BC011 cells were 301.5±46.9pg / ml and 502.4±121.3pg / ml, indicating that the four-generation CAR structures can effectively secrete IL-7.
[0398] (3) Detection of CAR molecules, dnTGFβRII, and IL-7 expression in CD133 CAR-T cells
[0399] The expression of CD133 CAR molecules, dnTGFβRII and IL-7 in Ctrl T, BW133-2, BW133-12, BW133-13, BW133-11B, BW133-6B, BW133-7B and BW133-7E cells was detected according to the above method.
[0400] The expression rate of CD133 CAR molecules is as follows Fig. 9 As shown in Figure 2, the CAR molecule expression rates of BW133-2, BW133-12, BW133-13, BW133-11B, BW133-6B, BW133-7B, and BW133-7E cells were 78.7%, 57.2%, 42.4%, 74.9%, 67.7%, 61.8%, and 70.0%, respectively, indicating that the CAR molecule was successfully expressed. The expression rate of dnTGFβRII is shown in Figure 2. Fig.10 As shown, the dnTGFβRII expression rates of BW133-13, BW133-11B, BW133-7B, and BW133-7E cells were 44.0%, 44.1%, 30.0%, and 28.2%, respectively, indicating that the dnTGFβRII molecule was successfully expressed in these four generations of CARs.
[0401] The expression level of IL-7 Fig.11 As shown in A, the IL-7 secretion levels of Ctrl T, BW133-2, BW133-12, BW133-13, BW133-6B, and BW133-7B were 6.0±0.9pg / ml, 6.6±0.2pg / ml, 7338.6±166.3pg / ml, and 5244.9±271.8pg / ml, respectively. The expression level of membrane-bound IL-7 is shown in Fig.11 As shown in B, the expression rate of membrane-bound IL-7 in BW133-7E was 17.3%, indicating that IL-7 can be successfully expressed in these four generations of CAR structures.
[0402] Example 4 Target cell detection
[0403] (1) Culture conditions of target cells
[0404] The tumor cells used in this example are all reporter cell lines expressing mCherry fluorescent protein: colorectal cancer cell HT55-Luc-mCherry (DMEM medium + 10% fetal bovine serum + 100U / ml penicillin + 100μg / ml streptomycin), SW620-Luc-mCherry (Leibovitz L-15 medium + 10% fetal bovine serum + 100U / ml penicillin + 100μg / ml streptomycin), HCT116-TGFβ-Luc-mCherry and HT29-TGFβ-Luc-mCherry (McCoy's 5A medium + 10% fetal bovine serum + 100U / ml penicillin + 100μg / ml streptomycin); gastric cancer cell HGC-27-Luc-mCherry, pancreatic cancer Capan-2-Luc-mCherry (McCoy's 5A medium + 10% fetal bovine serum + 100U / ml penicillin + 100μg / ml streptomycin) and liver cancer cell SK-Hep1-Luc-mCherry (EMEM medium + 10% fetal bovine serum + 100U / ml penicillin + 100μg / ml streptomycin).
[0405] (2) Detection of CEA expression in target cells
[0406] Wash the cells to be tested twice with PBS and resuspend them in FACS buffer. Add the AF700-labeled anti-CEA antibody to the cell suspension to be tested according to the antibody instructions and incubate at 4°C for 60 minutes. Use the target cells incubated with the corresponding isotype antibody as a negative control, and use flow cytometry to detect the CEA expression rate of the target cells.
[0407] The cells to be tested were washed twice with PBS and resuspended with FACS buffer. According to the antibody instructions, the PE-Cy7 labeled anti-CD133 antibody was added to the cell suspension to be tested and incubated at 4°C for 60 minutes. The target cells incubated with the corresponding isotype antibody were used as negative controls, and the CD133 expression rate of the target cells was detected by flow cytometry. FlowJo software was used for analysis, and the results are shown in Table 1.
[0408] Table 1 Expression rates of CEA and CD133 in tumor cells
[0409]
[0410]
[0411] Example 5 Study on enhanced TIL cell function
[0412] (1) Detection of enhanced TIL cell killing effect
[0413] SK-Hep1-Luc-mCherry was used to detect the killing effect of enhanced TIL cells. The target cells were digested and counted, with a concentration of 1×10 4 The target cells were seeded into a 96-well plate at a density of / well. 1×10 4 / hole or 2×10 4 / well TIL cells for co-culture. On the other hand, to investigate the function of dnTGFβRⅡ, 10ng / ml TGFβ was added to the co-culture system, and the changes in target cell area over time were detected using the IncuCyte live cell analyzer. The smaller the target cell area, the higher the degree of target cell death and the better the T cell killing effect.
[0414] The results are as follows Fig.12 As shown. The killing effects of BW197-2 TIL, BWTG TIL, and BW7TG TIL groups were significantly better than those of the Ctrl TIL control group. As the number of target cell stimulations increased, the killing effect of BW197-2 was significantly weakened. On the 11th day of co-culture with target cells, BWTG TIL and BW7TG TIL cells still maintained a strong killing effect, but the killing effect of BW7TG TIL was significantly stronger than that of other groups (P<0.05) ( Fig.12 ). This suggests that activating the IL-7 pathway and inhibiting the TGFβ pathway simultaneously can unexpectedly and significantly enhance the ability of TIL cells to resist the immunosuppression of the tumor microenvironment, while further enhancing their killing effect on tumor cells.
[0415] (2) IFN-γ release level of enhanced TIL cells
[0416] The concentrations of effector cells and target cells were adjusted with culture medium and inoculated into 96-well plates at a ratio of 1:1 so that the total number of cells was 1×10 5 / well (i.e. the number of effector cells and target cells are 0.5×10 5 / well). Then, 10 ng / ml TGF-β1 was added, and three replicates were added to each group. The cells were placed in a 37°C, 5% CO2 incubator for co-culture. After 72 hours, the culture supernatant was collected and the concentration of IFN-γ in the supernatant was detected by ELISA.
[0417] The results are as follows Fig.13 As shown. The IFN-γ release levels of Ctrl TIL, BW197-2 TIL, BWTG TIL, and BW7TG TIL were 8417.8±1004.7pg / ml, 10712.3±1521.3pg / ml, 37561.7±3846.0pg / ml, and 52859.2±4101.4pg / ml, respectively. The IFN-γ release level of BW7TG TIL was significantly higher than that of other groups (P<0.05). This indicates that the combined expression of IL-7 and dnTGFβRII can synergistically increase the activation level of TIL cells in the tumor microenvironment with high TGFβ concentration.
[0418] Example 6 Functional study of CAR-T cells
[0419] (1) Detection of CEA CAR-T cell killing effect
[0420] According to the flow cytometry results of the above target antigens, HT55-Luc-mCherry was selected to detect the killing effect of CAR-T cells. The target cells were digested and counted, with a concentration of 1×10 4 The target cells were seeded into a 96-well plate at a density of / well. 1×10 4 / hole or 2×10 4 / well T cells were co-cultured. On the other hand, to investigate the function of dnTGFβRⅡ, 10ng / ml TGFβ was added to the co-culture system, and the changes in target cell area over time were detected using the IncuCyte live cell analyzer. The smaller the target cell area, the higher the degree of target cell death and the better the T cell killing effect.
[0421] The results are as follows Fig.14As shown. Although BC001 and BC010 have a certain killing ability on target cells, the area of target cells still increased significantly on the 5th day of co-culture, indicating that the killing effect of BC001 and BC010 was inhibited by TGFβ. On the contrary, CAR-T cells BC011 expressing IL-7 and dnTGFβRⅡ can effectively and continuously inhibit the growth of target cells, and the killing effect is significantly stronger than that of other groups (P<0.05). This shows that the combined expression of IL-7 and dnTGFβRⅡ can effectively resist the inhibitory effect of TGFβ on T cells and enhance the killing ability of CAR-T cells against tumors.
[0422] (2) Detection of CD133 CAR-T cell killing effect
[0423] According to the flow cytometry results of the above target antigens, HCT116-Luc-mCherry was selected to detect the killing effect of CAR-T cells. The target cells were digested and counted, with a concentration of 1×10 4 The target cells were seeded into a 96-well plate at a density of / well. 1×10 4 / hole or 2×10 4 On the other hand, to investigate the function of dnTGFβRⅡ, 10ng / ml TGFβ was added to the co-culture system, and the long-term killing effect was detected using the IncuCyte live cell analyzer.
[0424] The results are as follows Fig.15 As shown. Similar to the results of CEA CAR-T cells, the BW133-13 group had a significantly stronger killing effect on tumor cells than the other groups (P<0.05). This result shows that the combined expression of IL-7 and dnTGFβRⅡ can effectively resist the inhibitory effect of TGFβ on T cells and enhance the killing ability of CAR-T against tumors.
[0425] (3) In vivo tumor inhibition experiment.
[0426] The target cells SW620 in the logarithmic growth phase and in good growth condition were collected by trypsin digestion, washed once with physiological saline, and the cell density was adjusted to 3×10 7 / ml. 100 μl of cell suspension was injected subcutaneously on the right side of B-NDG mice near the armpit, that is, 3×10 6 When the average tumor volume is 50-100 mm 3 CAR-T cells (1×10 7 / ) and Ctrl T cells (1×10 7 The day of injection of the test substance was recorded as the 0th day of treatment, and the tumor size was measured every week.
[0427] The results are as follows Fig.16 In the SW620 subcutaneous tumor model, the tumor volume of the BW133-13 group co-expressing IL-7 and dnTGFβRII was 654.3±255.8mm on day 25 after CAR-T cell infusion. 3 , which was significantly smaller than that of the BW133-2 control group (tumor volume was 1503.2±365.4mm 3 )(P<0.05). Although the tumor volume of the BW133-12 group co-expressing IL-7 and CCL19 had a tendency to shrink on the 14th day after the injection of CAR-T cells, the mice subsequently developed obvious side effects and died, indicating that the CAR-T cells have certain safety risks.
[0428] The above results indicate that inhibiting the TGFβ signaling pathway while activating the IL-7 pathway can not only maintain the T cell-enhancing effect of IL-7, but also unexpectedly significantly reduce the toxic side effects in vivo, which is safer than the existing technology of jointly expressing IL-7 and CCL19.
[0429] Example 7 CAR-T cell indication study
[0430] (1) Detection of the killing effect of CAR-T cells expressing IL-7 and dnTGFβRII on various solid tumor cells
[0431] In order to further improve the safety of IL-7 and dnTGFβRII CAR-T cells, IL-7 was fused with dnTGFβRII to express IL-7, so that IL-7 was anchored on the membrane of T cells through dnTGFβRII to obtain BW133-7E cells. At the same time, in order to study whether CAR-T cells that jointly express IL-7 and dnTGFβRII are also suitable for the treatment of malignant solid tumors other than colorectal cancer. HCT116-TGFβ-Luc-mCherry, HT-29-Luc-mCherry, HGC-27-Luc-mCherry, and Capan-2-Luc-mCherry cells were used to detect the killing effect of CAR-T cells. The target cells were digested and counted, and 1×10 4 The target cells were seeded into a 96-well plate at a density of / well. 1×10 4 / hole or 2×10 4 After adding TGFβ to the co-culture system, the long-term killing effect was detected using the Incucyte live cell analyzer.
[0432] The results are as follows Fig.17As shown in the figure, the killing effect of each experimental group was significantly better than that of the Ctrl T control group. As the number of target cell stimulations increased, CAR-T cells expressing IL-7 and dnTGFβRII fusion protein had a stronger effect on HCT116-Luc-mCherry colorectal cancer cells ( Fig.17 A) HT-29-Luc-mCherry colorectal cancer cells ( Fig.17 B) Capan-2-Luc-mCherry pancreatic cancer cells ( Fig.17 C) and HGC-27-Luc-mCherry gastric cancer cells ( Fig.17 D) had a significantly stronger killing effect than other groups (P<0.05).
[0433] Ctrl T, BW133-2 and BW133-7E cells were cultured in 96-well plates at different starting cell densities. AO / PI staining was performed after 72 h and the number of live cells was counted.
[0434] When the initial cell density was 1×10 5 / ml to 2×10 5 / ml, the cell proliferation fold of the BW133-7E group was not significantly different from that of the BW133-2 group ( Fig.18 A and Fig.18 B) When the initial cell density is 5×10 5 / ml, the expansion times of BW133-2 group was 1.48±0.13 times, and the expansion times of BW133-7E group was 2.08±0.19 times, which were significantly higher than those of BW133-2 group (P<0.05, Fig.18 C). The above results show that the cell proliferation ability of CAR-T cells expressing IL-7 and dnTGFβRII fusion protein can be self-regulated according to cell density. When accumulated in tumor lesions, the cell proliferation ability can be significantly improved, while it will not proliferate uncontrollably in non-tumor sites.
[0435] discuss
[0436] For the treatment of solid tumors, current immune cell therapies have many shortcomings. For example, traditional second-generation CAR-T cells have a short survival time in the body and weak expansion ability. On the basis of second-generation CAR-T cells, the combined expression of IL-7 can effectively promote the proliferation, survival, and immune memory of T cells. Studies have shown that further combined expression of IL-7 and chemokines CCL19 or CCL21, although it can promote the infiltration and survival of CAR-T cells into tumor sites, still fails to effectively solve the inhibitory effect of the immunosuppressive microenvironment in solid tumors on immune cells.
[0437] On the one hand, knocking down or knocking out TGFβ receptors in immune cells, or overexpressing dominant inhibitory mutants of TGFβ receptors (such as dnTGFβRII) can effectively block the endogenous TGFβ signaling pathway in cells, reduce the inhibitory effect of TGFβ on immune cells, and thus maintain the activity of immune cells in the tumor microenvironment. However, although these technologies can improve the killing effect of T cells in the tumor microenvironment to a certain extent, they cannot maintain the memory and survival ability of CAR-T cells in the body.
[0438] On the other hand, in order to solve the problems of the inhibitory effect of the tumor microenvironment and the short duration and poor memory of engineered immune cells in vivo, some studies have co-expressed a fusion protein composed of the TGFβRII extracellular domain and the IL-7RA intracellular domain on the basis of CD19 CAR-T to reverse the inhibitory signal of TGFβ into an activation signal of IL-7. However, the complete IL-7 activation signal requires IL-2RG and IL-7RA to form a complex and conduct together. Therefore, the fusion protein can only transduce signals through the IL-7RA intracellular domain, and the degree of activation is incomplete. In addition, since this technology requires the presence of TGFβ to activate the IL-7 pathway of immune cells. Therefore, when the concentration of TGFβ in the environment where the immune cells are located is low, it is difficult to maintain their own survival through the IL-7 pathway.
[0439] In the present invention, by up-regulating IL-7 and simultaneously down-regulating the TGFβ pathway, the activation degree of the IL-7 signal of the engineered immune cells is increased and the resistance to the tumor microenvironment is significantly provided, thereby significantly and synergistically increasing the IFN-γ release level of the immune cells and enhancing the killing effect on tumor cells, thereby synergistically improving the efficacy of the engineered immune cells. Experiments have shown that the engineered immune cells of the present invention (taking CAR-T cells or TIL as an example) have significantly improved immune cell proliferation ability, significantly reduced exhaustion, and significantly enhanced resistance to an immunosuppressive environment. In the present invention, the risk of toxic side effects caused by overexpression of IL-7 is unexpectedly reduced by optimizing the structure of IL-7 and dnTGFβRII.
[0440] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference separately. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.
Claims
1. An engineered immune cell, characterized in that: The engineered immune cells are T cells, TIL cells, or NK cells, and the immune cells have the following characteristics: (a) the immune cells express exogenous IL-7 protein; and (b) The immune cells express exogenous TGFβRII dominant inhibitory mutant protein or shRNA targeting endogenous TGFβRII transcripts; wherein the TGFβRII dominant inhibitory mutant is membrane-bound; Wherein, the amino acid sequence of the TGFβRII dominant inhibitory mutant is shown in SEQ ID No: 9 or SEQ ID No: 34; The nucleotide sequence of the shRNA expression frame is shown in SEQ ID No: 18, SEQ ID No: 19, SEQ ID No: 20, SEQ ID No: 21 or SEQ ID No:
22.
2. The engineered immune cell according to claim 1, characterized in that The IL-7 protein is membrane-bound or secreted.
3. The engineered immune cell according to claim 1, characterized in that The immune cells express a chimeric antigen receptor (CAR), wherein the CAR targets surface markers of tumor cells.
4. The engineered immune cell according to claim 1, characterized in that The structure of the IL-7 protein is shown in Formula Z as follows: AH-TM-D(Z) In the formula, A is IL-7 protein, or an active fragment or a mutant thereof; H is none or hinge region; TM is none or transmembrane domain; D is no or degradation domain; the "-" is a connecting peptide or peptide bond.
5. The engineered immune cell according to claim 1, characterized in that The structures of the IL-7 protein and TGFβRII dominant inhibitory mutant are shown in Formula I: Z0-Z1-Z2-D(I) In the formula, One of Z0 and Z2 is IL-7 protein, and the other is a dominant inhibitory mutant of TGFβRII; Z1 is none or a connecting peptide; D is the absence or degradation domain; The "-" means nothing, a connecting peptide or a peptide bond.
6. The engineered immune cell according to claim 5, characterized in that The TGFβRII dominant inhibitory mutant protein can be replaced by a shRNA expression frame targeting the endogenous TGFβRII transcript with a sequence of SEQ ID No:
10.
7. The engineered immune cell according to claim 3, characterized in that The structure of the CAR is shown in Formula II: L-scFv1-H-TM-C-CD3ζ-D(II) In the formula, L is none or a signal peptide sequence; scFv1 is an antigen-binding domain that targets surface markers of tumor cells; H is no or hinge region; TM is the transmembrane domain; C is the co-stimulatory signaling domain; CD3ζ is a cytoplasmic signaling sequence derived from CD3ζ; D is the absence or degradation domain; The "-" is a connecting peptide or peptide bond.
8. The engineered immune cell according to claim 7, characterized in that The surface marker of the tumor cells is CD133 or CEA.
9. The engineered immune cell according to claim 7, characterized in that In addition to the first CAR shown in Formula II, the CAR-T cell further contains a second CAR for targeting a second antigen, and the structure of the second CAR is shown in Formula III: L-scFv2-H-TM-C-CD3ζ-D(III) In the formula, L is none or a signal peptide sequence; scFv2 is an antigen binding domain targeting a surface marker of a second tumor cell; H is none or hinge region; TM is the transmembrane domain; C is the co-stimulatory domain; CD3ζ is a cytoplasmic signaling sequence derived from CD3ζ; D is the absence or degradation domain; The "-" is a connecting peptide or peptide bond.
10. A method for preparing the engineered immune cell according to claim 1, characterized in that: The following steps are involved: (A) providing an immune cell to be modified; and (B) Transforming the immune cells so that the immune cells express exogenous IL-7 protein and exogenous TGFβRII dominant inhibitory mutant protein or shRNA targeting endogenous TGFβRII transcripts, thereby obtaining the engineered immune cells of claim 1.
11. A preparation, characterized in that The preparation contains the engineered immune cell as claimed in claim 1, and a pharmaceutically acceptable carrier, diluent or excipient.
12. A use of the engineered immune cell according to claim 1, characterized in that: Used for preparing medicines or preparations for preventing and / or treating cancer.
13. A kit for preparing the engineered immune cell according to claim 1, characterized in that: The kit comprises a container, and located within the container: (1) a first nucleic acid sequence comprising a first expression cassette for expressing IL-7; and (2) A second nucleic acid sequence comprising a second expression cassette for expressing a dominant inhibitory mutant of TGFβRII or a shRNA targeting an endogenous TGFβRII transcript.
